A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

por Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.
Publicado 2023